항정신병약물 치료에 부분적인 반응을 보인 조현병 환자에 대한 아미설프라이드 병용요법의 효과와 안전성에 관한 연구

Objectives The response of schizophrenia or schizoaffective disorder patients to antipsychotics remains insufficient. Therefore, augmentation with additional antipsychotics is common in clinical practice. This study examined the efficacy and safety of amisulpride augmentation in schizophrenia patients partially responsive to antipsychotics. Methods Twenty-nine schizophrenia or schizoaffective disorder patients without treatment response to antipsychotics monotherapy were included in this study. Psychotic symptoms were evaluated using Brief Psychiatry Rating Scale (BPRS), Clinical Global Impression-Severity (CGI-S), and Clinical Global Impression-Improvement (CGI-I). The side effects were evaluated using Barnes Akathisia Rating Scale (BARS) and Simpson-Angus Scale (SAS) at baseline, 4 weeks, 8 weeks, and 12 weeks after the amisulpride augmentation. Results Among the 29 patients, 28 completed the study. At week 12, the mean BPRS score (p KCI Citation Count: 0